ARRY News Alert Array Biopharma Inc (ARRY) 4.64 12/25/2014 1

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Array Biopharma Inc (ARRY) 4.64 $ARRY

Biotech Stocks Technical Report -- Achillion Pharma, Arrowhead Research, Sunesis Pharma, Array BioPharma, and Seattle Genetics
PR Newswire - Mon Dec 22, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Arrowhead Research Corporation (NASDAQ: ARWR), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Array BioPharma Inc. (NASDAQ: ARRY), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, December 19, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,804.80, up 0.15% and the NASDAQ Composite closed at 4,765.38, up 0.36%. The S&P 500 finished the session 0.46% higher at 2,070.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 816.95, up 0.41%, with the index advancing 9.33% in the previous three months. Register for your complimentary reports on these five stocks at:
SGEN: 31.10 (-0.14), ARWR: 6.35 (+0.07), ACHN: 13.06 (+1.22), SNSS: 2.48 (-0.03), ARRY: 4.64 (+0.07)

Cardiomyopathy - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/qz4fhf/cardiomyopathy) has announced the addition of the "Cardiomyopathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cardiomyopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cardiomyopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned - Array BioPharma Inc. - Torrent Pharmaceuticals Limited - LG Life Sciences, Ltd. - Genethon - Fibrotech Therapeutics Pty. Ltd. - Beech Tree Labs, Inc. For more information visit http://www.researchandmarkets.com/research/qz...iomyopathy
ARRY: 4.64 (+0.07)

Oncothyreon secures exclusive license to HER2 inhibitor
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 9:50AM CST

ONTY: 1.89 (+0.01), ARRY: 4.64 (+0.07)

Array BioPharma Advances To All Systems Go, Collects $85 Million
Clinically Sound Investor - at Seeking Alpha - Fri Dec 12, 8:13AM CST

ARRY: 4.64 (+0.07), EXEL: 1.29 (-0.01)

Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380
GlobeNewswire - Fri Dec 12, 6:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that Array BioPharma Inc. (Nasdaq:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380.
ONTY: 1.89 (+0.01), ARRY: 4.64 (+0.07)

Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), INCY: 71.57 (+1.99), AMGN: 160.67 (+3.15), ARRY: 4.64 (+0.07)

Array BioPharma (ARRY) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:43AM CST
Array BioPharma (ARRY) Shares March Higher, Can It Continue?
ARRY: 4.64 (+0.07)

Array BioPharma, Inc. (ARRY) in Focus: Stock Soars 14.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:18AM CST
Array BioPharma, Inc. (ARRY) was a big mover last session, as the company saw its shares rise by over 14% on the day.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), AFFX: 9.80 (+0.05), ARRY: 4.64 (+0.07)

After Yesterday's Rally of 14.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Dec 04, 4:32PM CST
Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $4.38 to a high of $4.84. Yesterday, the shares gained 14.3%, which took the trading range above the 3-day high of $4.04 on volume of 17.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARRY: 4.64 (+0.07)

Why Array Biopharma Inc. Stock Roared Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 04, 2:59PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Array Biopharma , a clinical-stage...
GSK: 42.85 (+0.11), NVS: 93.91 (+0.66), ARRY: 4.64 (+0.07)

Array BioPharma Regains Binimetinib Rights from Novartis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:00PM CST
Shares of Array BioPharma Inc. (ARRY) shot up in after-market hours trading after the company announced reaching a definitive agreement with Novartis (NVS) to regain full worldwide rights to oncology candidate binimetinib, an MEK inhibitor.
BIIB: 340.89 (+5.13), GSK: 42.85 (+0.11), ARRY: 4.64 (+0.07), NVS: 93.91 (+0.66)

Array Biopharma Up 17.3%, Shares Break Through Resistance (ARRY)
Comtex SmarTrend(R) - Thu Dec 04, 10:06AM CST
Array Biopharma (NASDAQ:ARRY) is one of today's best performing low-priced stocks, up 17.3% to $4.59 on 7.9x average daily volume. Array Biopharma has traded 10.5 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has outperformed the Dow (17.3% to the Dow's -0.4%) and outperformed the S&P 500 (17.3% to the S&P's -0.5%) during today's trading.
ARRY: 4.64 (+0.07)

Array BioPharma (ARRY) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Dec 04, 7:55AM CST

ARRY: 4.64 (+0.07)

Array set for gap up at the open
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 6:37AM CST

ARRY: 4.64 (+0.07)

Array BioPharma to regain global rights to cancer therapy
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 5:33PM CST

GSK: 42.85 (+0.11), NVS: 93.91 (+0.66), ARRY: 4.64 (+0.07)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 4:39PM CST

TLYS: 9.47 (-0.03), HE: 33.35 (+0.17), WWWW: 19.23 (-0.03), PES: 5.60 (+0.13), ARO: 2.30 (-0.03), AVGO: 100.72 (-0.06), LDOS: 44.41 (+0.10), GST: 2.47 (-0.03), CSH: 22.16 (-0.46), ARRY: 4.64 (+0.07)

Array Biopharma Regains Rights to Cancer Drug From Novartis
at The Street - Wed Dec 03, 3:01PM CST
The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.
NVS: 93.91 (+0.66), ARRY: 4.64 (+0.07)

Array To Regain Worldwide Rights To Binimetinib
PR Newswire - Wed Dec 03, 3:01PM CST
Array BioPharma Inc. (NASDAQ: ARRY) today announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected in the first half of 2015, and remain subject to regulatory approval. Array had previously granted Novartis worldwide exclusive rights to develop and commercialize binimetinib under a 2010 License Agreement, which will terminate and be superseded by a new set of agreements between the parties.
ARRY: 4.64 (+0.07), NVS: 93.91 (+0.66)

Array BioPharma To Present At The Piper Jaffray And Oppenheimer 2014 Healthcare Conferences
PR Newswire - Tue Nov 25, 1:00PM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the following upcoming conferences. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: www.arraybiopharma.com.
ARRY: 4.64 (+0.07)

Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 3.02 (-0.05), CRIS: 1.29 (+0.04), IMMU: 4.41 (+0.13), PCYC: 121.84 (+1.15), ONCY: 0.49 (unch), PFE: 31.42 (-0.03), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), JNJ: 104.59 (+0.31), SNTA: 2.63 (+0.02), NVS: 93.91 (+0.66), XLRN: 38.80 (+0.80), ARRY: 4.64 (+0.07), CELGZ: 3.34 (-0.01), EXEL: 1.29 (-0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 82

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 5

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 131

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 96

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 135

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 253

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 18

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 176

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading

Top 5 Most Recently Viewed Articles

Class Action Lawsuit: CarMax Investors, Time to Act Now!

Updated Category News Views 232

Class Action Lawsuit for CarMax Investors Investors in CarMax, Inc. (NYSE: KMX) have found themselves facing a significant legal opportunity. The Rosen Law Firm, noted for its focus on protecting investor rights, has initiated a class action lawsuit that specifically addresses the concerns of securitiesholders. This lawsuit applies to purchasers of CarMax securities from...

Continue Reading
Plumbing Pitfalls: When Water Heater Noises Spell Trouble

Updated Category News Views 33

Understanding the Clamor from Your Water Heater The hustle and bustle of everyday life often drown out the less important noises. But when your water heater starts making a ruckus, maybe it's time to listen. From the keen ears of Jared Voss, a plumbing expert with his roots dug deep in Clinton, Iowa, we get the lowdown on what these noises could mean for your plumbing....

Continue Reading
Walmart Enhances Shopping Experience with Inclusive Carts

Updated Category News Views 288

Walmart Launches Caroline's Carts to Enhance Shopping Experience Today, Walmart is taking a big step toward inclusivity by introducing Caroline’s Carts in its stores across Tennessee. These specially designed shopping carts aim to assist caregivers who look after both children and adults with disabilities, making the shopping experience easier for everyone involved....

Continue Reading
Innovative Cancer Treatments by Cyncado Enhance Tumor Regression

Updated Category News Views 191

Introduction to Promising Cancer Treatment Strategies AlphaTON Capital Corp (NASDAQ: ATON) is making significant strides through its subsidiary Cyncado Therapeutics, particularly in the realm of oncology. Recently, they unveiled their latest preclinical studies focusing on the dynamic interaction between selective A2B and A2A receptor antagonists and cancer vaccines....

Continue Reading
Vertex Stock Insights: Recent Insider Trading Highlights

Updated Category News Views 42

Significant Trading Activity at Vertex Inc. Recently, it was made known that ITEM SECOND IRR TRUST FBO ANNE MARIE WESTPHAL, a 10% owner at Vertex (NASDAQ: VERX), executed a notable insider transaction. This insider sell, documented through an SEC filing, included 75,175 shares, accumulating a transaction value of approximately $3,018,885. As the market opened the...

Continue Reading